English, Article edition: Cost Effectiveness of Imatinib Compared with Interferon-alpha or Hydroxycarbamide for First-Line Treatment of Chronic Myeloid Leukaemia Kim Dalziel; Ali Round; Ruth Garside; ...

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/119876
Physical Description
  • article
Language
  • English

Edition details

Title
  • Cost Effectiveness of Imatinib Compared with Interferon-alpha or Hydroxycarbamide for First-Line Treatment of Chronic Myeloid Leukaemia
Author
  • Kim Dalziel
  • Ali Round
  • Ruth Garside
  • Ken Stein
Physical Description
  • article
Notes
  • Objective: To evaluate the cost utility of imatinib compared with interferon (IFN)-alpha or hydroxycarbamide (hydroxyurea) for first-line treatment of chronic myeloid leukaemia. Design and Setting: A cost-utility (Markov) model within the setting of the UK NHS and viewed from a health system perspective was adopted. Transition probabilities and relative risks were estimated from published literature. Costs of drug treatment, outpatient care, bone marrow biopsies, radiography, blood transfusions and inpatient care were obtained from the British National Formulary and local hospital databases. Costs (Lstg , year 2001-03 values) were discounted at 6%. Quality-of-life (QOL) data were obtained from the published literature and discounted at 1.5%. The main outcome measure was cost per QALY gained. Extensive one-way sensitivity analyses were performed along with probabilistic (stochastic) analysis. Results: The incremental cost-effectiveness ratio (ICER) of imatinib, compared with IFNalpha, was Lstg 26_180 per QALY gained (one-way sensitivity analyses ranged from Lstg 19_449 to Lstg 51_870) and compared with hydroxycarbamide was Lstg 86_934 per QALY (one-way sensitivity analyses ranged from Lstg 69_701 to Lstg 147_095) [Lstg 1 =​ $US1.691 =​ _1.535 as at 31 December 2002]. Based on the probabilistic sensitivity analysis, 50% of the ICERs for imatinib, compared with IFNalpha, fell below a threshold of approximately Lstg 31_000 per QALY gained. Fifty percent of ICERs for imatinib, compared with hydroxycarbamide, fell below approximately Lstg 95_000 per QALY gained. Conclusions: This model suggests, given its underlying data and assumptions, that imatinib may be moderately cost effective when compared with IFNalpha but considerably less cost effective when compared with hydroxycarbamide. There are, however, many uncertainties due to the lack of long-term data.
  • Antineoplastics, Chronic-myeloid-leukaemia, Cost-utility, Hydroxycarbamide, Imatinib, Interferon-alpha
  • RePEc:wkh:phecon:v:23:y:2005:i:5:p:515-526
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment